Monday, April 28, 2025

1:30 PM - 2:15 PM

Carron 2

---

Details

Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare blood disorder that significantly impacts patients' lives. Hear from local experts as they discuss various treatment options for PNH patients in the UK and present clinical case studies demonstrating the use of a new oral proximal inhibitor in the treatment pathway. This promotional symposium is organised and funded by Novartis Pharmaceuticals UK, Ltd, intended for UK healthcare professionals only. Prescribing Information will be available at the meeting for all Novartis brands mentioned. The speakers have been offered an honorarium for their involvement in this programme. UK | March 2025 | FA-11352217-1 Adverse Event Reporting: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

---

Speaker